RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

RxSight, an ophthalmic medical device company, has successfully closed its public offering of 2,053,571 shares of common stock at $56.00 per share. This includes the full exercise of underwriters' option to purchase an additional 267,857 shares, generating gross proceeds of $115 million. The offering was managed by BofA Securities, J.P. Morgan, and BTIG, with BofA Securities acting as the lead bookrunning manager. The automatic shelf registration statement and the final prospectus supplement were filed with the SEC on May 8, 2024. The proceeds are expected to support RxSight’s ongoing business activities and growth strategies.

Positive

• RxSight raised $115 million in gross proceeds from the public offering.
• The full exercise of underwriters' option to purchase additional shares indicates strong demand.
• BofA Securities, J.P. Morgan, and BTIG acted as managers, lending credibility to the offering.
• The automatic shelf registration statement became effective immediately, facilitating the swift execution of the offering.

Negative

• The offering will result in shareholder dilution as more shares enter the market.
• Gross proceeds of $115 million are before underwriting discounts, commissions, and other offering expenses, effectively reducing net proceeds.
• Increased shares in the market could potentially lead to a temporary drop in stock price.

ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight’s gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses.

BofA Securities acted as lead bookrunning manager of the offering and as representative of the underwriters. J.P. Morgan also acted as bookrunning manager for the offering. BTIG acted as co-manager of the offering.

RxSight filed an automatic shelf registration statement on Form S-3 relating to the shares of common stock offered in the public offering described above with the Securities and Exchange Commission (the “SEC”) on May 8, 2024, which became automatically effective upon filing. A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on May 8, 2024, and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, by telephone at (800) 294-1322 or by email at dg.prospectus_requests@bofa.com or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at prospectus-eq_fi@jpmchase.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The offering was only made by means of a prospectus supplement and accompanying prospectus.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight^® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens^® (LAL^®/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

FAQ

What did RxSight (RXST) announce on May 13, 2024?

On May 13, 2024, RxSight announced the closing of its public offering of common stock and the full exercise of underwriters' option to purchase additional shares.

How many shares did RxSight (RXST) offer in its public offering?

RxSight offered 2,053,571 shares of its common stock, including the exercise of underwriters' option to purchase 267,857 additional shares.

What was the price per share for RxSight's (RXST) public offering?

The shares were offered at $56.00 per share.

How much did RxSight (RXST) raise from its public offering?

RxSight raised $115.0 million in gross proceeds from the public offering.

Which firms managed RxSight's (RXST) public offering?

BofA Securities acted as the lead bookrunning manager, with J.P. Morgan and BTIG also serving as bookrunning managers.

When did RxSight (RXST) file the automatic shelf registration statement?

RxSight filed the automatic shelf registration statement on May 8, 2024.

Where can I find the final prospectus supplement for RxSight's (RXST) offering?

The final prospectus supplement is available on the SEC’s website at www.sec.gov.